Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review

DOI: https://doi.org/10.2147/LCTT.S388047

2023-02-04

Lung Cancer: Targets and Therapy

Abstract:Maria Concetta Nigro, 1 Paola Valeria Marchese, 1 Chiara Deiana, 1 Chiara Casadio, 1 Linda Galvani, 1 Alessandro Di Federico, 1 Andrea De Giglio 1, 2 1 Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Bologna, 40138, Italy; 2 Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy Correspondence: Paola Valeria Marchese, Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Via Albertoni 15, Bologna, 40138, Italy, Email Precision medicine has revolutionized the therapeutic management of cancer patients with a major impact on non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, where advances have been remarkable. Tissue biopsy, required for tumor molecular testing, has significant limitations due to the difficulty of the biopsy site or the inadequacy of the histological specimen. In this context, liquid biopsy, consisting of the analysis of tumor-released materials circulating in body fluids, such as blood, is increasingly emerging as a valuable and non-invasive biomarker for detecting circulating tumor DNA (ctDNA) carrying molecular tumor signatures. In advanced/metastatic NSCLC, liquid biopsy drives target therapy by monitoring response to treatment and identifying eventual genomic mechanisms of resistance. In addition, recent data have shown a significant ability to detect minimal residual disease in early-stage lung cancer, underlying the potential application of liquid biopsy in the adjuvant setting, in early detection of recurrence, and also in the screening field. In this article, we present a review of the currently available data about the utility and application of liquid biopsy in lung cancer, with a particular focus on the approach to different techniques of analysis for liquid biopsy and a comparison with tissue samples as well as the potential practical uses in early and advanced/metastatic NSCLC. Keywords: circulating tumor DNA, liquid biopsy, EGFR, minimal residual disease, sequencing technologies, lung cancer, early-stage, non-small cell lung cancer During the last decade, several tumor molecular alterations have been identified as drivers of cancer proliferation and survival, leading to the development of novel specific targeted agents for different tumors, including lung cancer. 1,2 Concerning non-small cell lung cancer (NSCLC), the advent of targeted therapy with tyrosine kinase inhibitors (TKIs) improved the overall patient outcomes with a better tolerability and safety profile when compared to platinum-based chemotherapy. Predominant targetable alterations in nonsquamous NSCLC are Epidermal growth factor receptor ( EGFR ), occurring in about 10–15% of Caucasian patients and up to 40% in Asian population, and Kirsten rat sarcoma virus ( KRAS )-mutations, present in 20–30% of patients, followed by Anaplastic lymphoma kinase ( ALK ) translocations (3–7%), v-raf murine sarcoma viral oncogene homolog B1 ( BRAF ) mutations (2–4%), c-mesenchymal-epithelial transition factor ( MET ) amplifications and exon 14 skipping mutations (2–4%), and c-ros oncogene 1 ( ROS1 ) (1–2%), rearranged during transfection (ret proto-oncogene or RET ) (1–2%) and Neurotrophic tyrosine receptor kinase ( NRTK ) fusions (0,5–1%). 3–11 However, many patients present a non-oncogene-addicted disease without any of the above-mentioned driver alterations. 3 Thus, the proportion of nonsquamous NSCLC patients presenting a non-oncogene addicted disease is progressively decreasing. 12 Conversely, the rate of actionable driver mutations among squamous NSCLC is very low, and international guidelines do not recommend comprehensive molecular testing. The expanding access to various molecular diagnostic strategies, such as next-generation sequencing (NGS) technique, immunohistochemistry and polymerase chain reaction method (PCR), allowed the routine use of molecular tumor assessment to determine the status of the most relevant molecular targets in NSCLC patients. 13,14 In fact, since 2018 and with the recent update of 2021, the International Society for the Study of Lung Cancer (IASLC) and the European Society of Medical Oncology (ESMO) recommended the adoption of NGS for the molecular assessment of patients with advanced NSCLC. 15 Nowadays, tumor tissue still represents the standard biological sample for molecular analysis. However, this approach has significant limitations due to the potentially difficult technical accessibility of particular sites of disease or the inadequacy of the histological sample for mole -Abstract Truncated-

English Else